

RESEARCH ARTICLE

# Effect of the Transient Pharmacological Inhibition of Mapk3/1 Pathway on Ovulation in Mice

Dayananda Siddappa<sup>1</sup>, Éline Beaulieu<sup>2</sup>, Nicolas Gévry<sup>2</sup>, Philippe P. Roux<sup>3</sup>, Vilceu Bordignon<sup>1</sup>, Raj Duggavathi<sup>1</sup>\*

**1** Department of Animal Science, McGill University, Ste-Anne-de-Bellevue, QC H9X 3V9, Canada, **2** Département de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada, **3** Institute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montreal, QC H3C 3J7, Canada

\* [raj.duggavathi@mcgill.ca](mailto:raj.duggavathi@mcgill.ca)



**OPEN ACCESS**

**Citation:** Siddappa D, Beaulieu É, Gévry N, Roux PP, Bordignon V, Duggavathi R (2015) Effect of the Transient Pharmacological Inhibition of Mapk3/1 Pathway on Ovulation in Mice. PLoS ONE 10(3): e0119387. doi:10.1371/journal.pone.0119387

**Academic Editor:** Jean-Marc A Lobaccaro, Clermont Université, FRANCE

**Received:** February 28, 2014

**Accepted:** January 30, 2015

**Published:** March 24, 2015

**Copyright:** © 2015 Siddappa et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** DS was funded by McGill Graduate Student Fellowship, Department of Animal Science Graduate Excellence Fellowship and RQR. This study was also partly funded by Réseau Québécois en Reproduction. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

Mitogen-activated protein kinase 3/1 (Mapk3/1) pathway is critical for LH signal transduction during ovulation. However, the mechanisms remain incompletely understood. We hypothesized that Mapk pathway regulates ovulation through transcriptional regulation of ovulatory genes. To test this hypothesis we used immature mice superovulated with equine and human chorionic gonadotropins (eCG and hCG) and PD0325901, to inhibit hCG-induced Mapk3/1 activity. Mice received either the inhibitor PD0325901 (25 µg/g, i.p.) or vehicle at 2h before hCG stimulation. Administration of the inhibitor abolished Mapk3/1 phosphorylation in granulosa cells. While vehicle-treated mice ovulated normally, there were no ovulations in inhibitor-treated mice. First, we analyzed gene expression in granulosa cells at 0h, 1h and 4h post-hCG. There was expected hCG-driven increase in mRNA abundance of many ovulation-related genes including *Ptgs2* in vehicle-treated granulosa cells, but not ( $P < 0.05$ ) in inhibitor-treated group. There was also reduced mRNA and protein abundance of the transcription factor, early growth response 1 (*Egr1*) in inhibitor-treated granulosa cells. We then used GRMO2 cell-line to test if *Egr1* is recruited to promoter of *Ptgs2* followed by chromatin immunoprecipitation with either *Egr1* or control antibody. Enrichment of the promoter regions in immunoprecipitants of *Egr1* antibody indicated that *Egr1* binds to the *Ptgs2* promoter. We then knocked down *Egr1* expression in mouse primary granulosa cells using siRNA technology. Treatment with *Egr1*-siRNA inhibited *Egr1* transcript accumulation, which was associated with reduced expression of *Ptgs2* when compared to control-siRNA treated granulosa cells. These data demonstrate that transient inhibition of LH-stimulated MAPK3/1 activity abrogates ovulation in mice. We conclude that Mapk3/1 regulates ovulation, at least in part, through *Egr1* and its target gene, *Ptgs2* in granulosa cells of ovulating follicles in mice.

## Introduction

Ovulation is a multi-gene, multi-step process involving complex signaling pathways, which facilitates synchronization of oocyte maturation and cumulus expansion with that of follicular rupture. It is unequivocal that preovulatory luteinizing hormone (LH) surge initiates these processes through remarkable changes in gene expression program of granulosa cells within ovulating follicles. Some of the important signaling pathways through which LH brings about ovulatory events are cAMP/Protein Kinase A (PKA) pathway, Mitogen-activated protein kinase 3/1 (Mapk3/1; ERK1/2) pathway and phosphatidylinositide 3-kinases (PI3K) pathway [1–4]. A recent study using granulosa-specific *Mapk3/1* knockout (KO) mice [5] provided *in vivo* evidence for the importance of Mapk3/1 signaling in LH signaling during ovulation.

Granulosa cells from *Mapk3/1* KO mice showed altered expression of hundreds of LH regulated genes [5], but which transcription factors act as mediators of their signals have not been completely identified [6]. Many transcription factors including nuclear receptor 5a2 (Nr5a2) [7] (CAAT/enhancer binding protein beta (Cebpb) [6], early growth response-1 (Egr1) [8] and Progesterone receptor (Pgr) [9] are critical LH signaling during ovulation. It was reported that 19% of the LH-driven genes were regulated in granulosa cells of both *Mapk3/1* and *Cebpa/b* conditional KO mice at 4h hCG [6]. This indicates that the rest 81% Mapk3/1-dependent genes are regulated by transcription factors other than Cebpa/b, which are yet to be identified.

While conditional KO model is a powerful tool to study physiological processes *in vivo*, it is not devoid of limitations. For example expression of the Cre-recombinase may not be active in all cells of interest, therefore, leading to incomplete gene deletion. On the other hand, pharmacologic method of inhibition of a protein's activity is economical, less time consuming and relatively simple compared to genetic manipulation. Moreover, using pharmacologic method one can inhibit protein activity transiently at a precise physiological stage. Limitations of pharmacologic methods include potential “off-target” effects. PD0325901 is specific inhibitor of Mapk-kinase (Map2k; MEK), which abrogates Mapk3/1 activity without cytotoxicity when administered as a single dose of 25µg/g bodyweight in mice [10,11]. More importantly, PD0325901 does not have off-target effects shown by other Map2k inhibitors, U0126 and PD98059 [12]. Therefore, PD0325901 treatment is an excellent alternative method to inhibit Mapk3/1 activity at precise time-points during follicular development.

The aim of our study was to identify novel transcription factors that play an important role downstream of Mapk3/1 signaling in the process of ovulation. We hypothesized that Mapk3/1 pathway regulates ovulation through transcriptional regulation of ovulatory genes. To test this hypothesis we employed an *in vivo* pharmacologic method of inhibition of Mapk3/1 activity without disrupting the *Mapk3/1* gene expression. Here we report our study exploring the effect of PD0325901 on ovulation in superovulated immature mice.

## Materials and Methods

### Animals and treatments

**Husbandry.** Inbred C57BL/6NCRl mice (Charles River) were housed in standard plastic rodent cages and maintained on a 12-h light/dark cycle with *ad libitum* feed (Teklad-Rodent irradiated Diet, Harlan) and water. The animal use protocol was approved by the Animal Care and Use Committee, McGill University.

**Ovarian superstimulation.** Immature mice (23–25d old) were first treated with equine chorionic gonadotropin (eCG; Sigma Life Sciences; 5 IU i.p.) to stimulate follicle development. Forty-eight hours later, mice were treated with human chorionic gonadotropin (hCG; Sigma

Life Sciences; 5 IU i.p.) to induce ovulation and luteinization. In this protocol, the ovulation occurs at 12–14h post-hCG [7,13,14].

**Inhibition of Mapk3/1 activity.** A potent selective Map2k (MEK) inhibitor PD0325901 (Selleckchem) was initially dissolved in DMSO (Fisher Scientific) to prepare a stock solution of 100 µg/µl concentration. A dosing solution of 2.5 µg/µl in 5% DMSO in saline was prepared just before treatment. For inhibition of Mapk3/1 activity, mice were administered with a single dose of PD0325901 (25 µg/g body weight, i.p.) 2h before hCG treatment. PD0325901 will be referred to as Map2k-inhibitor from here on for readers' simplicity. Mice treated with 5% DMSO in saline served as vehicle controls. We determined Mapk3/1 activity by determining the abundance of phosphorylated isoform of Mapk3/1 relative to its total isoform. The dose of Map2k-inhibitor was determined based on a preliminary experiment with doses of 10 and 25 µg/g 2 h before hCG treatment, of which the later dose resulted in consistent inhibition of Mapk3/1 activity.

### Ovulation rate and histology

To study the effect of inhibition of Mapk3/1 activity on ovulation rate, we counted cumulus oocyte complexes (COCs) from both oviducts of Map2k-inhibitor and vehicle treated mice at 18h post-hCG. Ovaries collected at 18h post-hCG from these mice were fixed in 10% neutral buffered formalin at 4°C for 2 days. Paraffin embedded ovaries were cut (4µ thickness) and sections were stained by hematoxylin and eosin for histological observation under Leica DM200 microscope attached with Leica EC3 camera.

### Granulosa cell collection and real-time PCR

Granulosa cells were collected by follicle puncture [15] at 0h, 1h and 4h post-hCG (N = 3 mice/group). Briefly, granulosa cells were collected by follicular puncture using 27G needle. The cell suspension was passed through a cell strainer (BD Falcon, Mississauga, ON, Canada; 40µm) to filter out cumulus–oocyte complexes. Pure populations of mural granulosa cells from both ovaries of each mouse were pooled together. Total RNA was purified from granulosa cells using Picopure RNA isolation kit (Arcturus Biosciences) followed by cDNA synthesis from 500 ng of RNA using iScript kit (Bio-Rad). We analyzed mRNA expression by real-time PCR as previously described [14] using the primers shown in Table 1. Expression data for each gene of interest was normalized to mean expression levels of four reference genes (*B2m*, *Sdha*, *L19* and *Gapdh*).

### Protein extraction and immunoblot analyses

Granulosa cells were collected in Laemmli buffer (Bio-rad) containing DTT (Omnipur), phosphatase and protease inhibitors (G Biosciences), and were boiled at 95°C for five minutes. Protein extracts were resolved by polyacrylamide electrophoresis and transferred to nitrocellulose membranes. After blocking with 5% milk in TBS-T, the membranes were incubated overnight at 4°C with primary antibodies (1:1000) followed by washing with TBS-T (3X 10 min each) and incubation with secondary antibody (1:10000) for 1hour at room temperature. The immunoblotted proteins were detected using Immun-Star Kit and Chemidoc Analyzer (BioRad). Whenever necessary, the membranes blotted with one primary antibody were stripped using stripping buffer (10% SDS, 0.5 M Tris-Hcl, DEPC H<sub>2</sub>O ml and 2-mercaptoethanol) and re-blotted with another antibody. Antibodies used: MAPK3/1 (#4695), phospho-MAPK3/1 (Thr202/Tyr204)(#4376) from Cell Signaling; EGR-1 (#sc-189x) from Santa cruz biotechnology; beta actin (ab8227) and Goat anti-rabbit-IgG (ab6721) from Abcam.

**Table 1. Primer sequence for real time PCR.**

Gene	Forward	Reverse
Adamts1	CATAACAATGCTGCTATGTGCG	TGTCCGGCTGCAACTTCAG
Areg	AGGGGACTACGACTACTCAG	GAAACTTGGCAGTGCATGGA
Egr1	TCGGCTCCTTTCCTCACTCA	CTCATAGGGTTGTTGCTCGG
Fshr	GTGCTACCAAGCTTCGAGCTAT	AAGGCCTCAGGGTTGATGTACAG
Has2	TGTGAGAGGTTTCTATGTGTCCT	ACCGTACAGTCCAAATGAGAAGT
Mapk1	CAGGTGTTGACGATAGGGC	TCTGGTGCTCAAAAGGACTGA
Mapk3	TCCGCCATGAGAATGTTATAGGC	GGTGTGATAAGCAGATTGG
Nr5a2	TCATGCTGCCAAAGTGGAGA	TGGTTTTGGACAGTTCGCTT
Pappa	CACAGGCAGAGCATCAGGAAG	TGCTTGCCATGAGGTAACCAG
Pgr	GGTGGAGGTCGTACAAGCAT	CTCATGGGTACCTGGAGTT
Ptgs2	TGAGCAACTATTCCAAACCAGC	GCACGTAGTCTTCGATCACTATC
Ptgs2-ChIP	CGCAACTCACTGAAGCAGAG	ATGGGGAGAACCCTTGCTTTT
Ptx3	CCTGCGATCCTGCTTTGTG	GGTGGGATGAAGTCCATTGTC
Scarb1	TTTGGAGTGGTAGTAAAAAGGGC	TGACATCAGGGACTCAGAGTAG
Star	CCGGGTGGATGGGTCAA	CACCTCTCCCTGCTGGATGTA
Tnfaip6	GGGATTCAAGAACGGGATCTTT	TCAAATTCACATACGGCCTTGG

doi:10.1371/journal.pone.0119387.t001

## GRMO2 cell culture and cAMP treatment

Mouse granulosa cell line, GRMO2 cells were cultured in DMEM/F12 (Wisent) supplemented with 5µg/ml insulin, 10µg/ml transferrin, 30pM selenite solution (Wisent), 2% fetal bovine serum (Wisent), penicillin-streptomycin (Wisent) and 3µg/ml BSA (Sigma) at 37°C and 5% CO<sub>2</sub> in a humidified incubator [16]. GRMO2 cells were treated with 1mM 8Br-cAMP (Sigma) or vehicle for 4 hours to simulate preovulatory LH treatment. Cells were then harvested after 4h (3–5 wells per treatment) for either gene expression analyses by qPCR detailed above or chromatin immunoprecipitation described below.

## Chromatin immunoprecipitation

Chromatin immunoprecipitation (ChIP) assays were performed as described previously [17]. Briefly, cells were cross-linked for 10 min at room temperature with 1% formaldehyde in PBS. Cells were then washed in PBS, resuspended in 200 µl of ChIP lysis buffer [1% SDS, 10 mm EDTA, 50 mm Tris-HCl (pH 8.0), and protease inhibitors], and sonicated. The chromatin solution was diluted 10-fold in ChIP dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mm EDTA, 16.7 mm Tris (pH 8.1), 16.7 mm NaCl, and protease inhibitors]; 5% of the lysate was used for purification of input DNA. Each sample was precleared by incubating with 2 µg of salmon sperm DNA/protein A-agarose 50% gel slurry (Roche Diagnostics) for 2 h at 4°C. Two to 4 µg of the Egr1 antibody or rabbit IgG was added and immunoprecipitated at 4°C overnight. The immunoprecipitant was collected using salmon sperm DNA/protein A-agarose and washed sequentially with the following buffers: low-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mm EDTA, 20 mm Tris-HCl (pH 8.1), and 150 mm NaCl], high-salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mm EDTA, 20 mm Tris-HCl (pH 8.1), and LiCl wash buffer [0.25 m LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mm EDTA, and 10 mm Tris-HCl (pH 8.1)], and Tris-EDTA buffer [10 mm Tris-HCl (pH 8.0) and 1 mm EDTA]. DNA-protein cross-links were reversed by incubation at 65°C overnight followed by proteinase K treatment. DNA was purified with Qiaquick PCR purification column (QIAGEN).

## Primary granulosa cell culture and siRNA-induced Egr1 gene knockdown

Granulosa cells from immature mice were collected, as described above, at 40h after eCG administration under aseptic conditions. Granulosa cell suspension was centrifuged at 1000g for 5 min at 37°C and pellet was re-suspended in electroporation medium (DMEM/F12 glutamax, Gibco 10565–018). Following cell counting using a hemocytometer, granulosa cells were diluted to a final concentration of  $0.2 \times 10^6$  cells in 10 $\mu$ l of DMEM/F12 media. Homogenous granulosa cell suspension was split into three parts. Each part was then mixed with either medium or control siRNA (at 20nM conc, Dharmacon, D-001210–05–05) or Egr1 siRNA smart pool (20nM, Dharmacon, M-040286–01). Electroporation was done using the Neon Transfection System (MPK 1096–772) and MBI microporator (Digital Bio) with the settings of 1000 volts, 30 millisecond and 3 pulses. Electroporated granulosa cells were plated in 24-well tissue culture plate (Sarstedt;  $0.2 \times 10^6$  cell/well) containing pre-warmed medium and incubated for 6 h at 37°C and 5% CO<sub>2</sub>. At the end of 6h incubation period, granulosa cells were treated with either forskolin (Fo; 10 $\mu$ M, Sigma, P3917) and phorbol-12-myristate (PMA; 20 $\mu$ M, Sigma, P1585) or medium for 4 h. Combined treatment with Fo and PMA (Fo+PMA) was used to mimic LH or hCG treatment *in vivo*. Following this treatment period, granulosa cells were harvested for either transcript or protein analysis.

## Statistical analysis

For data involving time and treatment, we used SigmaPlot 12.3 software two-way ANOVA followed by Holm-Sidak analysis for multiple comparisons. All data are represented as mean  $\pm$  SEM and  $p < 0.05$  was considered statistically significant.


## Results

### Map2k-inhibitor abolishes LH induced Mapk3/1 activity in granulosa cells

We first determined whether Map2k-inhibitor could be used as pharmacological inhibitor of granulosa cell Mapk3/1 activity during hCG-induced preovulatory follicle maturation in mice. Treatment with the inhibitor at 2h before hCG stimulation dramatically reduced the relative abundance of phospho-Mapk3/1 in granulosa cells of ovulating follicles compared to vehicle treatment ([Fig. 1](#)).

### Inhibition of Mapk3/1 activity in preovulatory follicles abrogates ovulation

Having established the experimental paradigm to efficiently inhibit hCG-induced Mapk3/1 activity using a pharmacological inhibitor, we asked whether this inhibition would have any effect on the ovulatory process. We found that Map2k-inhibitor treatment resulted in complete anovulation while vehicle treated mice ovulated normally ([Fig. 2A](#)). Histology of ovaries of control mice at 18h post-hCG showed numerous well-developed corpora lutea attesting to normal follicular rupture and luteinization ([Fig. 2B](#)). In contrast, ovaries of Map2k-inhibitor treated mice showed non-luteinized un-ruptured follicles with trapped oocytes. The follicles did not show any signs of luteinization and oocytes were in germinal vesicle stage surrounded by unexpanded cumulus ([Fig. 2C and D](#)).



**Fig 1. Transient inhibition of hCG induced Mapk3/1 activity by Map2k inhibitor treatment during ovarian superstimulation protocol.** Granulosa cells collected by follicular puncture from mice treated with PD0325901 showed absence of phosphorylation of Mapk3/1 at Thr302/Tyr204 compared to vehicle treated mice (n = 3 mice/group/time point).

doi:10.1371/journal.pone.0119387.g001


### Pharmacological inhibition of Mapk3/1 activity does not inhibit global transcription in granulosa cells, nor does it cause toxicity in mice

To investigate the mechanisms underpinning anovulation in the absence of Mapk3/1 activity, we undertook molecular phenotyping of granulosa cells collected at 0, 1 and 4h post-hCG in control and Map2k-inhibitor treated mice. Even though Map2k-inhibitor completely abolished Mapk3/1 activity in granulosa cells, it did not alter the relative mRNA abundance of *Mapk3/1* in granulosa cells (Fig. 3A). Expression pattern of *Fshr* and *Nr5a2* from 0h to 4h post-hCG was similar in granulosa cells of both control and Map2k-inhibitor treated mice (Fig. 3B). Interestingly, relative mRNA abundance of *Scarb1* and *Pappa* increased from 0h to 4h post-hCG in granulosa cells of both groups of mice (Fig. 3C). Further administration of vehicle or Map2k-inhibitor to mice did not produce any general signs of toxicity. These mice were active and appeared healthy upon physical examination. Paraffin sections of the liver and kidney of vehicle or Map2k-inhibitor treated mice were similar histologically and did not show any obvious signs of toxicity at 18h post-hCG (data not shown). Histologically ovary from Vehicle or Map2k-inhibitor treated mice did not showed any signs of toxicity, except absence of ovulation.

### Expression of hCG-induced ovulatory genes is decreased in granulosa cells lacking Mapk3/1 activity

Expression patterns of the genes implicated in the process of ovulation in vehicle and Map2k-inhibitor treated mice are shown in Fig. 4. One of the most important genes induced in granulosa cells by preovulatory LH surge is the prostaglandin synthase 2 (*Ptgs2*), which is critical for both follicular rupture and cumulus expansion [18–20]. At 4h post-hCG a 545-fold increase in *Ptgs2* mRNA was observed in granulosa cells of vehicle treated mice, but such a dramatic increase was absent ( $P < 0.001$ ) in granulosa cells of Map2k-inhibitor treated mice. The two other genes that play an important role in follicular rupture are progesterone receptor (*Pgr*) and A disintegrin and metalloproteinase with thrombospondin motifs 1 (*Adamts1*). In granulosa cells of vehicle treated mice *Pgr* mRNA was induced by 876-fold at 4h post-hCG compared to 0h hCG. Such a remarkable induction was completely absent in Map2k-inhibitor treated mice ( $P < 0.001$ ). Likewise, in Map2k-inhibitor treated mice, lack of Mapk3/1 activity abolished ( $P < 0.001$ ) a 9-fold increase in *Adamts1* mRNA observed in granulosa cells of






**Fig 2. Inhibition of hCG induced cumulus expansion, oocyte maturation and follicular rupture due to Map2k inhibitor treatment.** Treatment of immature mice with single dose of 25µg/g of PD0325901 resulted in anovulation compared to vehicle treated mice (A) during superovulation (n = 5 mice/ group). This anovulation as evidenced by trapped GV stage oocytes with compact cumulus cells (C&D) inside the preovulatory follicles at 18h hCG (n = 5 mice/ group). Vehicle treated mice showed well-developed corpus luteum (B) evidencing follicular rupture, ovulation and luteinization. CL—corpus luteum; GV—germinal vesicle.

doi:10.1371/journal.pone.0119387.g002

vehicle treated mice. Apart from *Ptgs2*, genes that mediate cumulus expansion include Hyaluronan synthase 2 (*Has2*), TNF $\alpha$ -induced protein 6 (*Tnfaip6*) and pentraxin 3 (*Ptx3*). In vehicle treated mice increase in *Has2* mRNA abundance was 8-fold at 4h post-hCG. Map2k-inhibitor treatment abrogated such an increase in the mRNA expression of *Has2* at 4h hCG ( $P < 0.001$ ). Similarly, 822-fold increase in *Ptx3* and 476-fold increase in *Tnfaip6* mRNA expressions seen in granulosa cells of vehicle treated mice was absent ( $P < 0.001$ ) in Map2k-inhibitor treated mice. Epidermal growth Factor (EGF)-like growth factors namely *Areg* (amphiregulin), *Ereg* (Epiregulin) and *Btc* (Betacellulin) have been implicated in oocyte meiotic maturation [3], of which we examined the expression pattern of *Areg*. Expression of *Areg* mRNA was highest at 1h hCG in vehicle treated granulosa cells, while its induction was reduced ( $P < 0.05$ ) by 50% in Map2k-inhibitor treated granulosa cells. *Cebpb* has been implicated in regulation of the terminal differentiation of granulosa cells during ovulation[6]. In vehicle treated mice granulosa cells *Cebpb* mRNA expression was highest at 1h hCG and it was down-regulated ( $P < 0.001$ ) in Map2k-inhibitor treated mice.




**Fig 3. Map2k inhibitor treatment does not shutdown the global transcription in granulosa cells.** Treatment of immature mice with single dose of 25µg/g of PD0325901 did not alter relative mRNA abundance of Mapk1 and Mapk3 (A). Expression of known hCG regulated genes like *Fshr* and *Nr5a2* (B) as well as hCG induced genes like *Scarb1* and *Pappa* (C) were also not altered in PD0325901 treated mice (n = 3mice/group/time point).

doi:10.1371/journal.pone.0119387.g003

### Inhibition of Mapk3/1 activity reduces the expression of transcription factor Egr1


Of the major transcription factors involved in ovulation mentioned in the introduction, Nr5a2 was not affected by Mapk3/1 inhibition (Fig. 3); *Pgr* was not expressed at 1h (Fig. 4), and *Cebpb* appears to be dispensable for early events of preovulatory LH signaling [6]. Therefore, we asked the question as to which transcription factor could mediate Mapk3/1 regulated transcription of LH-induced genes like *Ptgs2*. As it has been well established that LH/hCG induces





**Fig 4. Map2k inhibitor treatment reduces the expression of hCG induced ovulatory genes.** Treatment of immature mice with single dose of 25µg/g of PD0325901 inhibited the expression of hCG-induced genes involved in follicular rupture like *Ptgs2*, *Pgr*, *Adamts1*; genes involved in cumulus expansion like *Has2*, *Ptx3*, *Tnfaip6*; gene involved in oocyte meiotic maturation like *Areg* and luteinization like *Cebpb* (n = 3mice/group/time point). Mapk3/1 regulated LH induced genes like *Ptgs2*, *Ptx3* and *Tnfaip6* were not regulated by *Cebpb*.

doi:10.1371/journal.pone.0119387.g004



**Fig 5. Transient inhibition of Mapk3/1 reduces transcription and translation of transcription factor Egr1.** A) Treatment of immature mice with single dose of 25µg/g of PD0325901 inhibited the expression of hCG-induced expression of *Egr1* 1h and 4h hCG. B) Abundance of Egr1 protein in granulosa cells of the inhibitor and vehicle treated mice. Actb was used as loading control.

doi:10.1371/journal.pone.0119387.g005

*Egr1* expression in granulosa cells during ovulation [21,22], we hypothesized that this Mapk3/1 activity would be indispensable for the expression of the transcription factor, early growth response-factor 1 (*Egr1*). Indeed, inhibition of Mapk3/1 activity abolished ( $P < 0.001$ ) LH-induced mRNA expression of *Egr1* at 1h post-hCG as compared to vehicle treatment (Fig. 5A). Confirming these mRNA data, relative abundance of *Egr1* protein was remarkably absent in granulosa cells lacking Mapk3/1 activity at 1h and 4h post-hCG as compared to control granulosa cells (Fig. 5B).

### Egr1 binds to promoter regions of *Ptgs2*

In light of the data describe above, the obvious question was whether *Egr1* acts as a downstream effector of Mapk3/1 for induction of the ovulatory genes such as *Ptgs2*. To address this question, we performed ChIP analysis using *Egr1*-specific antibody. Because ChIP assays require large number of cells, we used a mouse granulosa cell line, GRMO2 cells. First, we

characterized gene expression pattern of GRMO2 cells in response to cAMP. GRMO2 cells stimulated with cAMP and granulosa cells from mice treated with hCG showed similar relative expression pattern genes like *Star*, *Ptgs2* and *Egr1* (Fig. 6A). To determine whether Egr1 binds to the promoters of ovulatory genes, we performed ChIP and qPCR using cAMP stimulated GRMO2 cells. Immunoprecipitation with Egr1-specific antibody showed that cAMP treatment of GRMO2 cells for 4 h increased the enrichment of the promoter of *Ptgs2* (region-159 to -33 relative to the transcription start site) compared to GRMO2 cells that were not treated with cAMP (Fig. 6B). However, there was no significant increase in amplification of the regions in GRMO2 cells with or without cAMP treatment when immunoprecipitation was done using rabbit IgG. These data clearly indicated that Egr1 is recruited to the promoter region of *Ptgs2* in response to cAMP treatment that is analogous to LH stimulation.

### Knockdown of Egr1 reduces *Ptgs2* transcript abundance


To further demonstrate the importance of Egr1 for *Ptgs2* expression, we used siRNA to knock-down Egr1 expression in mouse primary granulosa cells. Treatment with forskolin and PMA (Fo+PMA) dramatically induced the expression of ovulatory genes including *Egr1* and *Ptgs2* when compared to medium-treated granulosa cells (data not shown). Immunoblot assays revealed that inhibition of Mapk3/1 activity using PD0325901 abolished *Ptgs2* induction by treatment with Fo+PMA (Fig. 7A). Treatment of primary granulosa cells with *Egr1*-siRNA reduced Egr1 mRNA and protein abundance compared to levels of control siRNA treated cells (Fig. 7B). Relative mRNA levels of *Ptgs2* were 55% lower *Egr1*-siRNA treated granulosa cells as compared to control siRNA treated cells (Fig. 7B).

## Discussion

In the present study we show that transient pharmacological inhibition of Mapk3/1 activity using a single dose of the Map2k inhibitor, PD0325901 during preovulatory follicle maturation resulted in anovulation. This phenotype is similar to the one observed in granulosa-specific *Mapk3/1* KO mice [5]. Our results confirm that this anovulatory phenotype is due to downregulation of numerous genes involved in ovulation. The novel aspect this study is that we have identified the Egr1 as the downstream transcription factor that mediates transcription of genes involved in follicular rupture namely, *Ptgs2* and *Adamts1*.




Ovulation is a process of release of oocyte through rupture of preovulatory follicles [13], regulated by the preovulatory LH-surge. This complex process involves a remarkable gene expression program initiated by LH through multiple signaling pathways and numerous transcription factors. Mapk3/1 are highly conserved Ser/Thr kinases, which regulate cellular proliferation and differentiation [23] by modulating transcription, translation and post translational modifications of their targets [24]. A recent study [5] demonstrated, using granulosa-specific *Mapk3/1*-KO mice, that Mapk3/1 are critical for LH signaling in granulosa cells during ovulation. That study showed Cebpb as a downstream transcription factor responsible for several Mapk3/1 target genes.

Our results showed that transient inhibition of Mapk3/1 activity using single dose of Map2k-inhibitor completely inhibited ovulation in superovulated mice, a phenotype seen in granulosa-specific *Mapk3/1* KO mice [5]. Histology of ovary from inhibitor-treated mice showed disruption of processes of follicular rupture, oocyte maturation, cumulus expansion and luteinization. These phenotypes did not appear to be caused by potential cytotoxic effects of Map2k-inhibitor, as Mapk3/1 were normally expressed in granulosa cells of inhibitor treated mice. The high-density lipoprotein receptor Scarb1 is induced by LH in granulosa cells of mice [7,25] and monkeys [26]. Reduced ovulation rate was observed in *Pappa* KO mice [27],



**Fig 6.** A) Comparison of expression profile of ovulatory genes in granulosa cells from hCG treated mice and cAMP treated GRMO2 cells. Expression profiles of ovulatory genes like *Star*, *Ptgs2* and *Egr1* were similar at 0h, 1h and 4h after hCG or cAMP treatment in granulosa cells or cultured GRMO2 cells respectively. B) Binding of Egr1 transcription factor to *Ptgs2* promoter region (-159 to -33 relative to the transcription start site). Chromatin immunoprecipitation and qPCR using 4h cAMP treated GRMO2 cells showed the enrichment of promoter region containing Egr1 binding site (identified by bioinformatic analysis) in immunoprecipitants of Egr1 antibody indicating that Egr1 binds to *Ptgs2* promoter. Rabbit IgG was used as a control antibody.

doi:10.1371/journal.pone.0119387.g006



Fo + PMA	-	+	+
Con siRNA	-	+	-
Egr1-siRNA	-	-	+

**Fig 7. Inhibition of Mapk3/1 activity and knockdown of Egr1 results in reduced induction of Pgts2 in primary granulosa cells in vitro.** A) Treatment with PD0325901 decreased Fo+PMA induced increases in the abundance of Pgts2 protein relative to vehicle treated primary granulosa cells. B) Pre-treatment with Egr1-siRNA inhibited Fo+PMA induced expression of Egr1 when compared to control siRNA treatment in primary granulosa cells in vitro. This was associated with reduced abundance of Pgts2 transcript in Egr1-siRNA treated cells. Fo—forskolin; PMA—phorbol-12-myristate.

doi:10.1371/journal.pone.0119387.g007



indicating the Pappa may be important for ovulation. Given that both *Scarb1* and *Pappa*, were normally induced in Map2k-inhibitor treated mice, anovulation in these mice does not appear to be due to global abrogation of LH signaling. Indeed, it was previously reported that PD0325901 treatment at 25 ug/g dose, similar to the dose used in this study, did not have any toxic effects [10,11]. Therefore, it is possible to conclude that inhibition of Mapk3/1 activity in granulosa cells resulted in anovulation through inhibition of a specific set of gene involved in the ovulatory processes.

Genes that are induced by hCG and implicated in ovulatory process were remarkably down-regulated in granulosa cells of Map2k-inhibitor treated mice. Similar downregulation of multiple genes including, *Ptgs2*, *Pgr* and *Has2* was reported in granulosa-specific *Mapk3/1* KO mice [5]. *Ptgs2* appears to play a pleiotropic role during ovulation as ovaries of *Ptgs2* null mice presented absence of CLs, compromised cumulus expansion but normal follicle development with oocyte maturation [18]. On the other hand, *Adamts1* and *Pgr* have been implicated mainly in follicular rupture as mice lacking *Adamts1* [28] or *Pgr* [9] showed ovulatory defects with normal cumulus expansion and luteinization. Even pharmacological inhibition of *Pgr* using RU486 significantly decreased the number of ovulations [29]. Thus in light of these reports, our data of lack on LH-induced expression of *Ptgs2*, *Adamts1* and *Pgr* as a result of inhibition of Mapk3/1 activity indicate that Mapk3/1 regulate follicular rupture through transcriptional regulation of the aforementioned genes in granulosa cells.

In the present study Map2k-inhibitor treatment downregulated hCG-induced expression of *Has2*, *Tnfaip6* and *Ptx3* suggesting that Mapk3/1 play a critical role in cumulus expansion through transcriptional regulation of the genes involved in the process. Likewise, granulosa-specific *Mapk3/1* KO mice also showed down regulated cumulus expansion after hCG stimulation. This conclusion is well supported by observations that cumulus expansion is severely compromised in mice null for *Tnfaip6* [30], *Ptx3* [31] and *Has2* [32]. Further, inhibition of Mapk3/1 downregulated hCG-induced expression of *Areg* and *Btc*, which are important for cumulus expansion and oocyte meiotic maturation. Indeed, pharmacologic inhibition of Mapk3/1 using U0126 reduced the expression of LH-induced *Areg* and *Ereg* in luteinized human granulosa cells [1]. Also, U0126 treatment inhibited oocyte maturation in cultured large antral follicles [33]. Overall, our mRNA expression data confirm the importance of Mapk3/1 activity in the transcriptional regulation of ovulation-related genes in granulosa cells of ovulating follicles. Therefore, it is important to determine the transcription factors that act as downstream effectors of Mapk3/1 signaling in order to decipher the molecular mechanisms of the regulation of ovulation by this pathway.

Granulosa-specific *Mapk3/1* KO mice showed decreased expression of *Cebpb*, which was proposed to be one of the downstream effectors of Mapk3/1 signaling in regulating ovulation [5]. It was further demonstrated that granulosa-specific deletion of *Cebpa/b* genes resulted in complete anovulation [6], confirming the mediatory role of these transcription factors in Mapk3/1 signaling. However, this study also revealed that *Cebpa/b* accounted for 19% of Mapk3/1-regulated genes during early hours of preovulatory differentiation. Most importantly, LH-induced genes like *Areg*, *Ereg*, *Ptgs2*, *Tnfaip6* and *Ptex3* were unaffected in the absence of *Cebpa/b* in granulosa cells [6]. We also observed downregulation of *Cebpb* expression, which could not explain the dramatic perturbation of the ovulatory gene expression in Map2k-inhibitor treated mice. Therefore, our results along with the genetic studies above clearly demonstrate that Mapk3/1 signaling is complex and may involve several other transcription factors as downstream effectors to regulate gene expression program during ovulation.


Our obvious choice was the immediate early transcription factor, *Egr1*, which is rapidly and transiently induced by growth factors in many cell types. Our interest in *Egr1* was based on several reports. Mice null for *Egr1* were infertile and their ovaries showed follicles of all stages but

not corpus luteum [8,34], indicating that it may play a significant role in ovulation. Multiple signaling pathways including Mapk, protein kinase A and C signaling pathways are known to induce *Egr1* expression [35]. Most importantly, LH/hCG can transiently induce *Egr1* exclusively in granulosa cells preovulatory follicles mediating proliferation and/or differentiation during follicular growth, ovulation and luteinization [21,22]. In line with our hypothesis, inhibition of Mapk3/1 activity resulted in remarkable downregulation of hCG-induced *Egr1* mRNA and protein. These results clearly indicate that Mapk3/1 activity is indispensable for LH-induced *Egr1* expression in granulosa cells.

Several lines of evidence show that Mapk pathway is critical for *Egr1* expression in multiple cell types. Inhibition of Mapk3/1 pathway by Map2k inhibitor PD98059, but not Mapk14 or PI3K pathway, decreased hypoxia induced *Egr1* expression in mouse and human alveolar epithelial cells [36]. In bovine luteal cells PGF<sub>2α</sub> treatment induced *EGR1* through Mapk3/1 pathway and PD098059 challenge inhibited this *EGR1* induction [37]. In rat granulosa cells hCG-induced *Egr1* expression was co-regulated by Mapk3/1, cAMP response element binding protein (Creb) and *Egr1* itself [21]. However, Creb activity was not altered in granulosa cells null for *Mapk3/1* [5]. Similarly, inhibition of Mapk3/1 activity in the present study showed complete downregulation of *Egr1* despite unaltered *Creb* expression (data not shown). Taken together, these data suggest that Mapk3/1 signaling may be more critical than the classical cAMP/Creb pathway for LH-induced *Egr1* expression in granulosa cells. Further it has been shown that *Egr1* expression is regulated by the transcription factor, serum response factor (Srf) in multiple cell types including granulosa cells [28], gonadotropes [38] and endothelial cells [39]. Since Srf is a known target of Mapk3/1 [40], it is possible to speculate from our data that hCG-induced *Egr1* expression in granulosa cells requires Mapk3/1 kinase activity and the transcription factor Srf during ovulation.

To further link Mapk3/1 dependent *Egr1* expression to genes important for follicle rupture, we hypothesized that *Egr1* regulates LH-induced transcription of *Ptgs2*. To test this hypothesis we first used cAMP primed GRMO2 cells. GRMO2 cells have been previously used [16] to study LH-stimulated events in granulosa cells. Systematic analyses revealed that they faithfully recapitulate LH-induced gene expression program in response to cAMP challenge. CHIP analyses using *Egr1* antibody clearly demonstrated that *Egr1* binds to the promoter of *Ptgs2*. Inhibition of Mapk3/1 activity in primary mouse granulosa cells in vitro resulted in reduced expression of *Ptgs2* confirming that Mapk3/1 activity is indispensable for *Ptgs2* induction during ovulation. Finally, inhibition of *Egr1* induction using siRNA technology resulted in reduced expression of *Ptgs2* in primary granulosa cells, further confirming that *Egr1* regulates *Ptgs2* expression in granulosa cells. Our results are further supported by a previous study, which showed that overexpression of *EGR1* in bovine granulosa cells increased expression of *PTGS2* expression [41]. Even though *Egr1* KO mice are known to be infertile along with multiple ovarian defects [8], *Egr1* target genes have not been explored. With our study demonstrating regulation of *Ptgs2* expression by *Egr1*, it would be very interesting to explore these genes in granulosa cells *Egr1* KO mice.

In conclusion hCG induced Mapk3/1 activity during preovulatory follicle maturation regulates transcription of the genes involved in the process of cumulus expansion, oocyte maturation and follicular rupture. These LH-induced processes are severely compromised in response to a single dose of Map2k-inhibitor PD0325901. Our proposed mechanism for the role of Mapk3/1 is shown in Fig. 8. It is very well established that LH along with modulatory effects of EGF-like growth factors and their tyrosine kinase receptors induces phosphorylation of Mapk3/1. Our results here propose that *Egr1* is one of the Mapk3/1 regulated transcription factors that transactivates its target genes involved in follicular rupture such as *Ptgs2*. Finally, several Map2k-inhibitors are under advanced clinical trial for anti-cancer therapy. Since our data



**Fig 8. Transcriptional regulation of ovulatory genes by Mapk3/1 through Egr1 transcription factor.** Preovulatory LH surge induced Mapk3/1 activity regulates transcription of ovulatory genes such as *Ptgs2* through transcription factor Egr1. Inhibition of this LH-induced Mapk3/1 activity by Map2k inhibitor PD0325901 results in anovulation.

doi:10.1371/journal.pone.0119387.g008

here demonstrate that single dose of PD0325901 has an overwhelming inhibitory effect on ovulation in superovulated mice. These dramatic results warrant further detailed studies to test the effect of such inhibitors on ovarian function.

### Acknowledgments

We thank Profs. Sarah Kimmins, Jaswinder Singh and Luis Agellon for allowing us to use their laboratory facilities for this study. We also thank Ms. Eliza Rossi Komninou, Ms. Melissa Pansera, Ms. Yasmin Schuermann, Ms. Lisa Dupuis and Ms. Maaike Hibbein-Kirby for excellent technical assistance.

### Author Contributions

Conceived and designed the experiments: DS NG VB RD. Performed the experiments: DS EB. Analyzed the data: DS NG PPR VB RD. Contributed reagents/materials/analysis tools: NG PPR VB RD. Wrote the paper: DS RD.

### References

1. Ben-Ami I, Armon L, Freimann S, Strassburger D, Ron-EI R, Amsterdam A. (2009) EGF-like growth factors as LH mediators in the human corpus luteum. *Hum Reprod* 24: 176–184. doi: [10.1093/humrep/den359](https://doi.org/10.1093/humrep/den359) PMID: [18835871](https://pubmed.ncbi.nlm.nih.gov/18835871/)

2. Ashkenazi H, Cao X, Motola S, Popliker M, Conti M, Tsafirri A. (2005) Epidermal growth factor family members: endogenous mediators of the ovulatory response. *Endocrinology* 146: 77–84. PMID: [15459120](#)
3. Park JY, Su YQ, Ariga M, Law E, Jin SL, Conti M. (2004) EGF-like growth factors as mediators of LH action in the ovulatory follicle. *Science* 303: 682–684. PMID: [14726596](#)
4. Fan HY, Liu Z, Cahill N, Richards JS (2008) Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. *Mol Endocrinol* 22: 2128–2140. doi: [10.1210/me.2008-0095](#) PMID: [18606860](#)
5. Fan HY, Liu Z, Shimada M, Sterneck E, Johnson PF, Hedrick SM, et al. (2009) MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility. *Science* 324: 938–941. doi: [10.1126/science.1171396](#) PMID: [19443782](#)
6. Fan HY, Liu Z, Johnson PF, Richards JS (2011) CCAAT/Enhancer-Binding Proteins (C/EBP)-{alpha} and-{beta} Are Essential for Ovulation, Luteinization, and the Expression of Key Target Genes. *Mol Endocrinol* 25: 253–268. doi: [10.1210/me.2010-0318](#) PMID: [21177758](#)
7. Duggavathi R, Volle DH, Matakic C, Antal MC, Messaddeq N, Auwerx J, et al. (2008) Liver receptor homolog 1 is essential for ovulation. *Genes Dev* 22: 1871–1876. doi: [10.1101/gad.472008](#) PMID: [18628394](#)
8. Topilko P, Schneider-Maunoury S, Levi G, Trembleau A, Gourdji D, Driancourt MA, et al. (1998) Multiple pituitary and ovarian defects in Krox-24 (NGFI-A, Egr-1)-targeted mice. *Mol Endocrinol* 12: 107–122. PMID: [9440815](#)
9. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, et al. (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. *Genes Dev* 9: 2266–2278. PMID: [7557380](#)
10. Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, et al. (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. *Bioorg Med Chem Lett* 18: 6501–6504. doi: [10.1016/j.bmcl.2008.10.054](#) PMID: [18952427](#)
11. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 439: 358–362. PMID: [16273091](#)
12. Wauson EM, Guerra ML, Barylko B, Albanesi JP, Cobb MH (2013) Off-target effects of MEK inhibitors. *Biochemistry* 52: 5164–5166. doi: [10.1021/bi4007644](#) PMID: [23848362](#)
13. Richards JS, Russell DL, Ochsner S, Espey LL (2002) OVULATION: New Dimensions and New Regulators of the Inflammatory-Like Response. *Annual Review of Physiology* 64: 69–92. PMID: [11826264](#)
14. Dupuis L, Schuermann Y, Cohen T, Siddappa D, Kalaiselvanraja A, Pansera M, et al. (2014) Role of leptin receptors in granulosa cells during ovulation. *Reproduction* 147: 221–229. doi: [10.1530/REP-13-0356](#) PMID: [24256641](#)
15. Deroo BJ, Rodriguez KF, Couse JF, Hamilton KJ, Collins JB, Grissom SF, et al. (2009) Estrogen receptor beta is required for optimal cAMP production in mouse granulosa cells. *Molecular endocrinology* 23: 955–965. doi: [10.1210/me.2008-0213](#) PMID: [19324971](#)
16. Weck J, Mayo KE (2006) Switching of NR5A proteins associated with the inhibin alpha-subunit gene promoter after activation of the gene in granulosa cells. *Mol Endocrinol* 20: 1090–1103. PMID: [16423880](#)
17. Svolitelis A, Bianco S, Madore J, Huppe G, Nordell-Markovits A, Mes-Masson AM, et al. (2011) H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERalpha ligand dependency. *EMBO J* 30: 3947–3961. doi: [10.1038/emboj.2011.284](#) PMID: [21841772](#)
18. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, et al. (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. *Nature* 378: 406–409. PMID: [7477380](#)
19. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, et al. (1997) Multiple female reproductive failures in cyclooxygenase 2-deficient mice. *Cell* 91: 197–208. PMID: [9346237](#)
20. Micu MC, Micu R, Ostensen M (2011) Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. *Arthritis Care Res (Hoboken)* 63: 1334–1338. doi: [10.1002/acr.20510](#) PMID: [21618455](#)
21. Russell DL, Doyle KM, Gonzales-Robayna I, Pipaon C, Richards JS (2003) Egr-1 induction in rat granulosa cells by follicle-stimulating hormone and luteinizing hormone: combinatorial regulation by transcription factors cyclic adenosine 3',5'-monophosphate regulatory element binding protein, serum response factor, sp1, and early growth response factor-1. *Mol Endocrinol* 17: 520–533. PMID: [12554779](#)

22. Espey LL, Ujioka T, Russell DL, Skelsey M, Vladu B, Robker RL, et al. (2000) Induction of early growth response protein-1 gene expression in the rat ovary in response to an ovulatory dose of human chorionic gonadotropin. *Endocrinology* 141: 2385–2391. PMID: [10875238](#)
23. Ramos JW (2008) The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. *Int J Biochem Cell Biol* 40: 2707–2719. doi: [10.1016/j.biocel.2008.04.009](#) PMID: [18562239](#)
24. Sugden PH, Clerk A (1997) Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. *Cell Signal* 9: 337–351. PMID: [9376213](#)
25. Jimenez LM, Binelli M, Bertolin K, Pelletier RM, Murphy BD (2010) Scavenger receptor-B1 and luteal function in mice. *J Lipid Res* 51: 2362–2371. doi: [10.1194/jlr.M006973](#) PMID: [20404351](#)
26. Cherian-Shaw M, Puttabyatappa M, Greason E, Rodriguez A, VandeVoort CA, Chaffin CL. (2009) Expression of scavenger receptor-B1 and low-density lipoprotein receptor and differential use of lipoproteins to support early steroidogenesis in luteinizing macaque granulosa cells. *Endocrinology* 150: 957–965. doi: [10.1210/en.2008-0619](#) PMID: [18832102](#)
27. Nyegaard M, Overgaard MT, Su YQ, Hamilton AE, Kwintkiewicz J, Hsieh M, et al. (2010) Lack of functional pregnancy-associated plasma protein-A (PAPPA) compromises mouse ovarian steroidogenesis and female fertility. *Biol Reprod* 82: 1129–1138. doi: [10.1095/biolreprod.109.079517](#) PMID: [20130263](#)
28. Mittaz L, Russell DL, Wilson T, Brasted M, Tkalcic J, Salamonsen LA, et al. (2004) Adamts-1 is essential for the development and function of the urogenital system. *Biol Reprod* 70: 1096–1105. PMID: [14668204](#)
29. Iwamasa J, Shibata S, Tanaka N, Matsuura K, Okamura H (1992) The relationship between ovarian progesterone and proteolytic enzyme activity during ovulation in the gonadotropin-treated immature rat. *Biol Reprod* 46: 309–313. PMID: [1536908](#)
30. Fulop C, Szanto S, Mukhopadhyay D, Bardos T, Kamath RV, Rugg MS, et al. (2003) Impaired cumulus mucification and female sterility in tumor necrosis factor-induced protein-6 deficient mice. *Development* 130: 2253–2261. PMID: [12668637](#)
31. Varani S, Elvin JA, Yan C, DeMayo J, DeMayo FJ, Horton HF, et al. (2002) Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. *Mol Endocrinol* 16: 1154–1167. PMID: [12040004](#)
32. Su YQ, Sugiura K, Eppig JJ (2009) Mouse oocyte control of granulosa cell development and function: paracrine regulation of cumulus cell metabolism. *Semin Reprod Med* 27: 32–42. doi: [10.1055/s-0028-1108008](#) PMID: [19197803](#)
33. Su YQ, Denegre JM, Wigglesworth K, Pendola FL, O'Brien MJ, Eppig JJ. (2003) Oocyte-dependent activation of mitogen-activated protein kinase (ERK1/2) in cumulus cells is required for the maturation of the mouse oocyte-cumulus cell complex. *Dev Biol* 263: 126–138. PMID: [14568551](#)
34. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Eppig JJ. (1996) Abnormal splicing of the leptin receptor in diabetic mice. *Nature* 379: 632–635. PMID: [8628397](#)
35. Pagel JI, Deindl E (2011) Early growth response 1—a transcription factor in the crossfire of signal transduction cascades. *Indian J Biochem Biophys* 48: 226–235. PMID: [22053691](#)
36. Jones N, Agani FH (2003) Hyperoxia induces Egr-1 expression through activation of extracellular signal-regulated kinase 1/2 pathway. *J Cell Physiol* 196: 326–333. PMID: [12811826](#)
37. Hou X, Arvisais EW, Jiang C, Chen DB, Roy SK, Pate JL, et al. (2008) Prostaglandin F2alpha stimulates the expression and secretion of transforming growth factor B1 via induction of the early growth response 1 gene (EGR1) in the bovine corpus luteum. *Mol Endocrinol* 22: 403–414. PMID: [17916653](#)
38. Duan WR, Ito M, Park Y, Maizels ET, Hunzicker-Dunn M, Jameson JL. (2002) GnRH regulates early growth response protein 1 transcription through multiple promoter elements. *Mol Endocrinol* 16: 221–233. PMID: [11818496](#)
39. Wu SQ, Minami T, Donovan DJ, Aird WC (2002) The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells. *Blood* 100: 4454–4461. PMID: [12393577](#)
40. Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. *Growth Factors* 24: 21–44. PMID: [16393692](#)
41. Sayasith K, Brown KA, Lussier JG, Dore M, Sirois J (2006) Characterization of bovine early growth response factor-1 and its gonadotropin-dependent regulation in ovarian follicles prior to ovulation. *J Mol Endocrinol* 37: 239–250. PMID: [17032742](#)